Trial Profile

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacokinetics
Sponsors Novo Nordisk

Most Recent Events

01 Apr 2022 Results published in the Diabetes, Obesity and Metabolism
10 May 2021 Results of pooled analysis assessing clinical pharmacokinetics of oral Semaglutide published in the Clinical Pharmacokinetics
11 Jun 2019 Results evaluating effect of gastrointestinal disease on pharmacokinetics of semaglutide (n=55) were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com